# Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

> **NCT06569420** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 275 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- ALK-positive
- SAF-189s

## Interventions

- **OTHER:** Drug: Foritinib Succinate
- **OTHER:** Drug: Crizotinib

## Key facts

- **NCT ID:** NCT06569420
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-31
- **Primary completion:** 2025-07-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06569420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06569420, "Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06569420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*